Pfizer Ltd.: Premium Pharma Play Trading at Peak Multiples
NSE: PFIZER | BSE: 500680 | Sector: Healthcare / Pharmaceuticals | CMP: ₹4,507 | Market Cap: ₹20,620 Cr
Pfizer Limited is the Indian subsidiary of Pfizer Inc. (NYSE: PFE), the world's largest pharmaceutical company by revenue, commanding a 63.92% promoter (parent) holding and operating a focused branded formulation portfolio in India spanning vaccines, anti-infectives, women's health, pain, vitamins, and gastroenterology. The stock has emerged as a premium consumer-pharma compounder with FY26 OPM of 36%, ROCE of 24%, and a debt-free balance sheet, but trades at an elevated ~28x P/E that prices in continued execution.
Executive Summary
| Headline Metric | Value | Verdict |
|---|
| CMP | ₹4,507 | Near 52-week low; ~25% off highs |
| Market Cap | ₹20,620 Cr | Mid-cap pharma; top quartile quality |
| Stock P/E (TTM) | ~28x | Premium to sector (22x) |
| Book Value | ₹919 | Implied P/B ~4.9x |
| Dividend Yield | 1.65% | Consistent payer |
| ROCE | 24.2% | High-quality capital allocator |
| ROE | 18.0% | Sustainable without leverage |
| Debt/Equity | ~0.02x | Net cash company |
| Promoter Holding | 63.92% | Locked-in parent support |
| FY26 Sales Growth | +10.5% YoY | Volume-led acceleration |
| FY26 OPM | 36% | Sector-leading margins |
| FY26 EPS | ₹157.92 | Second-best in a decade |
One-Line Thesis: Pfizer India is a high-quality, debt-free branded pharma franchise trading at a deserved premium — buy on dips below ₹4,200 for a 3-year CAGR target of 12-15% with dividends.
§1. Business Overview
Pfizer Limited (formerly Wyeth Limited) is a publicly listed Indian pharmaceutical company that operates as a subsidiary of Pfizer Inc. (USA), the global biopharmaceutical giant. The Indian arm is one of the most respected branded formulation players in the country with a 75+ year operating history, a pan-India sales force, and a portfolio of ~150+ brands across 7 therapeutic areas.
Corporate Structure
| Attribute | Detail |
|---|
| Full Name | Pfizer Limited |
| NSE Ticker | PFIZER |
| BSE Code | 500680 |
| ISIN | INE182A01018 |
| Incorporated | 1950 (operations in India since then) |
| Parent Company | Pfizer Inc., New York, USA |
| Promoter Holding | 63.92% (Pfizer Inc.) |
| Listing Date | 1960s (BSE); 1995 (NSE) |
| Registered Office | Mumbai, Maharashtra |
| Manufacturing Sites | 3 (Goa, Aurangabad, Taloja) |
| Employees | ~2,800+ (FY25) |
| Field Force | ~2,000+ medical representatives |
| Distribution Reach | ~1,00,000+ retail chemists |
| Hospital Coverage | 8,000+ hospital accounts |
Brand Portfolio (Flagship Brands)
| Brand | Therapy Area | Indication | Market Position |
|---|
| Prevenar 13 | Vaccines | Pneumococcal disease (PCV) | #1 globally; market leader in India |
| Corex | Cough & Cold | Cough syrup (Codeine + CPM) | Legacy brand; declining post-NCD ban |
| Becosules | Vitamins | B-complex supplement | #1 prescribed B-complex in India |
| Combiflam | Pain | Ibuprofen + Paracetamol | Iconic mass-market brand |
| Folvite | Women's Health | Folic acid (5mg) | Dominant in OBGYN segment |
| Minipress XL | Cardiology | Prazosin (hypertension) | Niche leader |
| Magnex | Anti-infectives | Cefoperazone + Sulbactam (antibiotic) | Hospital-grade cephalosporin |
| Lyrica | Pain / Neuro | Pregabalin (neuropathic pain) | Top-3 brand by value |
| Eliquis | Cardiology | Apixaban (DOAC anticoagulant) | Global blockbuster; launched in India |
| Dolonex | Pain | Piroxicam (NSAID) | Legacy brand; mature |
| Oxytrol | Women's Health | Oxybutynin (urology) | Specialty brand |
| Caltrate | Vitamins | Calcium + Vitamin D3 | OTC mega-brand in calcium |
| Centrum | Vitamins | Multivitamin | Premium OTC positioning |
| Enbrel | Biologics | Etanercept (rheumatoid arthritis) | Specialty biologic |
| Champix | CNS | Varenicline (smoking cessation) | Niche leader |
Business Segments
| Segment | FY26 Revenue (Est. ₹Cr) | % of Total | Growth YoY | OPM (Est.) |
|---|
| Anti-Infectives | ~650 | ~26% | +12% | ~38% |
| Vaccines (Prevenar 13) | ~550 | ~22% | +18% | ~45% |
| Vitamins & OTC | ~480 | ~19% | +9% | ~32% |
| Pain & Analgesics | ~340 | ~13% | +7% | ~30% |
| Women's Health | ~280 | ~11% | +11% | ~40% |
| Cardiology / CNS | ~150 | ~6% | +15% | ~35% |
| Other (Hospital, Biologics) | ~70 | ~3% | +8% | ~25% |
| Total | ~2,520 | 100% | +10.5% | ~36% |
| Plant Location | State | Key Products | Capacity Utilization (Est.) |
|---|
| Goa Plant | Goa | Sterile injectables, cephalosporins | ~85% |
| Aurangabad Plant | Maharashtra | Orals, topicals, tablets | ~75% |
| Taloja Plant | Maharashtra | APIs (some imported intermediates) | ~70% |
Leadership Team
| Name | Designation | Background |
|---|
| Mr. R.A. Shah | Chairman (Non-Executive) | Veteran pharma industry leader |
| Mr. Meenakshi Nevatia | Managing Director | 20+ years Pfizer global |
| Mr. Milind Patil | Chief Financial Officer | Finance veteran |
| Mr. Anil Jain | VP - Medical | Pharma medical affairs |
§2. Latest Quarter Deep Dive — Q4 FY26 (Mar 2026)
The March 2026 quarter (Q4 FY26) is the latest reporting period and shows a mature, margin-led, demand-resilient franchise that is not dependent on a single product to drive performance.
Q4 FY26 Standalone P&L
| Line Item | Q4 FY26 (₹Cr) | Q4 FY25 (₹Cr) | YoY % | Q3 FY26 (₹Cr) | QoQ % |
|---|
| Revenue from Operations | 629 | 592 | +6.3% | 645 | -2.5% |
| Total Expenses | 393 | 364 | +8.0% | 417 | -5.8% |
| Operating Profit (EBIT) | 236 | 228 | +3.5% | 228 | +3.5% |
| Operating Margin (OPM%) | 38% | 38% | Flat | 35% | +300 bps |
| Other Income | 50 | 217 | -77% | -20 | NM |
| Interest Expense | 2 | 3 | -33% | 2 | 0% |
| Depreciation | 15 | 16 | -6% | 14 | +7% |
| Profit Before Tax (PBT) | 269 | 426 | -37% | 192 | +40% |
| Tax | 69 | 95 | -27% | 50 | +38% |
| Tax Rate (%) | 26% | 22% | +400 bps | 26% | 0 bps |
| Net Profit (PAT) | 200 | 331 | -39.6% | 142 | +40.8% |
| EPS (₹) | 43.68 | 72.34 | -39.6% | 31.00 | +40.9% |
Sequential Quarter (Last 5 Quarters Trajectory)
| Quarter | Sales (₹Cr) | YoY Sales Growth | OPM % | Net Profit (₹Cr) | EPS (₹) |
|---|
| Q4 FY25 (Mar 2025) | 592 | +3.3% | 38% | 331 | 72.34 |
| Q1 FY26 (Jun 2025) | 603 | +13.6% | 35% | 192 | 41.91 |
| Q2 FY26 (Sep 2025) | 642 | +11.5% | 36% | 189 | 41.32 |
| Q3 FY26 (Dec 2025) | 645 | +19.6% | 35% | 142 | 31.00 |
| Q4 FY26 (Mar 2026) | 629 | +6.3% | 38% | 200 | 43.68 |
Q4 FY26 — Key Observations
| Observation | Detail | Investment Implication |
|---|
| Revenue Growth Moderation | +6.3% YoY vs. +19.6% in Q3 | Seasonal softness, not demand issue |
| OPM Expansion | 38% in Q4 vs. 35% in Q3 | Operating leverage intact |
| Net Profit Decline | -40% YoY on lower other income | Base effect — FY25 Q4 had one-time gains |
| EPS Beat | ₹43.68 vs. consensus est. ₹38 | In-line to slightly above street |
| Volume Growth | Estimated +5-6% | Mid-single-digit pricing power |
| Prevenar 13 Performance | Estimated +20% YoY | Vaccine portfolio remains flagship |
| Becosules Growth | Estimated +8% YoY | OTC franchise stable |
| Combiflam Growth | Estimated +5% YoY | Mature brand, low single-digits |
| Corex Decline | Estimated -25% YoY | Continued post-NCD pressure |
| Eliquis Trajectory | Estimated +50% YoY | New launch driving growth |
| Free Cash Flow Q4 | Estimated ~₹200 Cr | Strong cash generation |
| Working Capital | CCC of 132 days (FY26) | Slight improvement from 177 days in FY25 |
Quarterly Margin Progression
| Quarter | Sales (₹Cr) | Operating Profit (₹Cr) | OPM % | Notes |
|---|
| Q4 FY23 (Mar 23) | 573 | 182 | 32% | Pre-momentum period |
| Q1 FY24 | 531 | 111 | 21% | One-time expense impact |
| Q2 FY24 | 575 | 183 | 32% | Recovery |
| Q3 FY24 | 540 | 153 | 28% | Seasonal |
| Q4 FY24 | 547 | 189 | 35% | Year-end strength |
| Q1 FY25 | 563 | 177 | 32% | Stable |
| Q2 FY25 | 589 | 189 | 32% | Stable |
| Q3 FY25 | 538 | 146 | 27% | Seasonal dip |
| Q4 FY25 | 592 | 228 | 38% | Year-end + one-off |
| Q1 FY26 | 603 | 210 | 35% | Steady |
| Q2 FY26 | 642 | 230 | 36% | Acceleration |
| Q3 FY26 | 645 | 228 | 35% | Sequential peak |
| Q4 FY26 | 629 | 236 | 38% | New margin peak |
Cash Generation — Trailing Twelve Months (TTM)
| Metric | TTM Value (FY26) | Comment |
|---|
| Cash from Operations | ₹968 Cr | Best in 5 years |
| Free Cash Flow | ₹944 Cr | After capex of just ₹24 Cr |
| CFO/OP Ratio | 105% | High-quality earnings |
| CFO/Net Profit Ratio | ~134% | Earnings backed by cash |
| Dividend Payout (FY26) | 48% | Strong return to shareholders |
| Net Cash on B/S | ~₹3,500+ Cr | Cash-rich, debt-free |
Pfizer India's 5-year financial journey is the story of margin expansion, de-leveraged growth, and a clean balance sheet. The company has demonstrated resilience through COVID, post-COVID normalization, and now the post-Corex era.
5-Year P&L Summary (Standalone)
| Line Item (₹Cr) | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | 5Y CAGR |
|---|
| Revenue | 2,239 | 2,611 | 2,425 | 2,193 | 2,281 | 2,520 | +2.4% |
| YoY Growth % | +4.0% | +16.6% | -7.1% | -9.6% | +4.0% | +10.5% | - |
| Total Expenses | 1,526 | 1,775 | 1,616 | 1,555 | 1,540 | 1,616 | +1.1% |
| Operating Profit | 712 | 836 | 809 | 638 | 742 | 904 | +4.9% |
| OPM % | 32% | 32% | 33% | 29% | 33% | 36% | +400 bps |
| Other Income | 81 | 63 | 134 | 185 | 344 | 139 | +11.4% |
| Interest | 15 | 11 | 13 | 15 | 8 | 9 | -9.7% |
| Depreciation | 109 | 115 | 106 | 62 | 61 | 58 | -11.8% |
| PBT | 669 | 773 | 824 | 746 | 1,016 | 976 | +7.8% |
| Tax | 171 | 160 | 200 | 195 | 248 | 254 | +8.2% |
| Tax % | 26% | 21% | 24% | 26% | 24% | 26% | Flat |
| Net Profit | 498 | 613 | 624 | 551 | 768 | 722 | +7.7% |
| Net Margin % | 22% | 23% | 26% | 25% | 34% | 29% | +700 bps |
| EPS (₹) | 108.77 | 133.90 | 136.38 | 120.52 | 167.79 | 157.92 | +7.7% |
| Dividend/Share (₹) | 35.0 | 35.0 | 40.0 | 35.0 | 165.0 | 75.0 | +16.5% |
5-Year Balance Sheet Snapshot (Standalone)
| Item (₹Cr) | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|
| Equity Capital | 46 | 46 | 46 | 46 | 46 | 46 |
| Reserves & Surplus | 2,347 | 2,819 | 3,162 | 3,550 | 4,172 | 4,157 |
| Total Net Worth | 2,393 | 2,865 | 3,208 | 3,596 | 4,218 | 4,203 |
| Borrowings | 63 | 39 | 41 | 40 | 41 | 70 |
| Other Liabilities | 810 | 997 | 752 | 593 | 653 | 649 |
| Total Liabilities | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 | 4,922 |
| Fixed Assets (Net) | 894 | 869 | 749 | 713 | 724 | 678 |
| CWIP | 3 | 1 | 8 | 0 | 8 | 20 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 2,369 | 3,030 | 3,244 | 3,516 | 4,180 | 4,224 |
| Total Assets | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 | 4,922 |
| Net Debt (Cash) | -2,330 | -2,780 | -3,121 | -3,510 | -4,131 | -4,087 |
| Book Value/Share (₹) | 522 | 625 | 699 | 784 | 919 | 917 |
| Debt/Equity | 0.03x | 0.01x | 0.01x | 0.01x | 0.01x | 0.02x |
5-Year Cash Flow Statement (Standalone)
| Item (₹Cr) | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|
| Cash from Operations | 427 | 667 | 356 | 257 | 660 | 968 |
| Cash from Investing | -469 | -575 | -36 | 54 | -71 | -562 |
| Cash from Financing | -1,571 | -181 | -346 | -235 | -205 | -798 |
| Net Cash Flow | -1,613 | -88 | -26 | 75 | 383 | -392 |
| Free Cash Flow (CFO-Capex) | 410 | 654 | 292 | 291 | 783 | 944 |
| CFO/OP % | 89% | 107% | 81% | 64% | 110% | 105% |
| Capex | 17 | 13 | 64 | -34 | -123 | 24 |
| Dividend Paid | 160 | 160 | 181 | 161 | 753 | 343 |
5-Year Ratio Analysis
| Ratio | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | Trend |
|---|
| OPM % | 32% | 32% | 33% | 29% | 33% | 36% | ↑ Expanding |
| Net Margin % | 22% | 23% | 26% | 25% | 34% | 29% | ↑ Volatile |
| ROCE % | 23% | 29% | 26% | 22% | 22% | 24% | → Stable |
| ROE % | 21% | 21% | 19% | 15% | 18% | 17% | → Stable |
| Debtor Days | 18 | 20 | 23 | 31 | 31 | 26 | ↑ Increasing |
| Inventory Days | 199 | 173 | 175 | 200 | 214 | 195 | ↑ Increasing |
| Days Payable | 130 | 102 | 91 | 77 | 68 | 89 | ↓ Decreasing |
| Cash Conversion Cycle | 87 | 91 | 107 | 154 | 177 | 132 | ↑ Worsening |
| Working Capital Days | 3 | -14 | 1 | 24 | 23 | 9 | → Stable |
| Asset Turnover (x) | 0.69x | 0.67x | 0.61x | 0.52x | 0.46x | 0.51x | ↓ Declining |
| Dividend Payout % | 32% | 26% | 29% | 29% | 98% | 48% | → Variable |
5-Year Return Metrics
| Metric | Value | Rank in Nifty Pharma |
|---|
| 5-Year Sales CAGR | +2.4% | Below median |
| 5-Year Net Profit CAGR | +7.7% | Above median |
| 5-Year EPS CAGR | +7.7% | Above median |
| 5-Year Book Value CAGR | +12.0% | Top quartile |
| Average ROCE (5Y) | +24.2% | Top decile |
| Average ROE (5Y) | +18.6% | Top quartile |
| 5-Year Stock Price CAGR | ~+10-12% | Mid-pack |
| 5-Year Total Return | ~+75-80% | With dividends |
Margin Expansion Story (FY21 to FY26)
| Period | OPM % | Cumulative OPM Expansion (bps) | Driver |
|---|
| FY21 | 32% | Baseline | COVID demand + low base |
| FY22 | 32% | 0 bps | Prevenar 13 ramp-up |
| FY23 | 33% | +100 bps | Product mix improvement |
| FY24 | 29% | -300 bps | Corex ban impact, one-time cost |
| FY25 | 33% | +100 bps | Cost rationalization |
| FY26 | 36% | +400 bps | Pricing + mix + operating leverage |
| Total FY21-FY26 | +400 bps | Strong expansion | Multi-year operational excellence |
Working Capital Cycle (Days)
| Year | Receivables | Inventory | Payables | Cash Conversion Cycle | Working Capital Days |
|---|
| FY15 | 32 | 191 | 165 | 58 | 7 |
| FY16 | 26 | 167 | 157 | 36 | -9 |
| FY17 | 20 | 148 | 178 | -10 | -47 |
| FY18 | 29 | 147 | 245 | -69 | -57 |
| FY19 | 30 | 189 | 213 | 6 | -16 |
| FY20 | 29 | 198 | 197 | 31 | -8 |
| FY21 | 18 | 199 | 130 | 87 | 3 |
| FY22 | 20 | 173 | 102 | 91 | -14 |
| FY23 | 23 | 175 | 91 | 107 | 1 |
| FY24 | 31 | 200 | 77 | 154 | 24 |
| FY25 | 31 | 214 | 68 | 177 | 23 |
| FY26 | 26 | 195 | 89 | 132 | 9 |
Dividend Track Record
| Year | Dividend/Share (₹) | Total Payout (₹Cr) | Payout Ratio | Yield at CMP |
|---|
| FY21 | 35 | 161 | 32% | 0.78% |
| FY22 | 35 | 161 | 26% | 0.78% |
| FY23 | 40 | 184 | 29% | 0.89% |
| FY24 | 35 | 161 | 29% | 0.78% |
| FY25 | 165 | 759 | 98% | 3.66% |
| FY26 | 75 | 345 | 48% | 1.66% |
| Total (5Y) | 385 | 1,771 | ~45% | ~8.5% |
§4. Industry & Competition — Pharma Peer Comparison
The Indian pharmaceutical industry is the 3rd largest globally by volume and 13th by value, growing at ~10-12% CAGR. Pfizer India competes primarily in the branded formulation (chronic + acute) and vaccine segments, with a focus on specialty / super-specialty categories.
Industry Snapshot
| Industry Metric | Value | Notes |
|---|
| Indian Pharma Market Size (FY26) | ~$50-55 Billion | Growing at 10-12% CAGR |
| Domestic Branded Market | ~$25 Billion | ~50% of total |
| Export Market | ~$27 Billion | Largest generic exporter globally |
| # of Companies (Listed) | ~500+ | Highly fragmented |
| Top 10 Companies' Market Share | ~40% | Concentrated gradually |
| Top 50 Companies' Market Share | ~70% | Long tail of small players |
| Therapy Area Growth | Cardiac +12%, Anti-Diabetic +14%, Vaccines +18% | Chronic segment booming |
| Regulator | CDSCO, DCGI, NPPA | Pricing control on essential drugs |
| Patent Regime | TRIPS compliant since 2005 | Product patents enforced |
Pharma Peer Comparison (Top Peers)
| Company | CMP (₹) | Mkt Cap (₹Cr) | P/E (TTM) | ROCE % | ROE % | OPM % | Rev Growth (5Y) | Net Debt/Equity | Div Yield % |
|---|
| Pfizer Ltd. | 4,507 | 20,620 | 28.5x | 24% | 18% | 36% | +2.4% | -0.97x (Net Cash) | 1.65% |
| Cipla | 1,485 | 119,500 | ~25x | 20% | 15% | 22% | +9.5% | -0.10x | 1.0% |
| Dr Reddy's | 1,225 | 102,000 | ~19x | 18% | 16% | 22% | +11.0% | -0.05x | 0.6% |
| Sun Pharma | 1,790 | 428,000 | ~37x | 22% | 17% | 30% | +10.5% | -0.15x | 0.8% |
| Lupin | 2,150 | 98,000 | ~28x | 18% | 14% | 20% | +8.5% | +0.20x | 0.5% |
| Gland Pharma | 1,820 | 38,000 | ~22x | 16% | 13% | 25% | +12.0% | -0.30x | 0.4% |
| JB Chemicals | 1,650 | 25,500 | ~32x | 22% | 19% | 24% | +11.5% | -0.20x | 0.6% |
Peer Ranking — Where Pfizer Stands
| Metric | Pfizer Rank (out of 7) | Position | Comments |
|---|
| Market Cap | #5 | Mid-tier | Smaller than top 4 generic majors |
| P/E Multiple | #5 | Mid-pack | Premium for quality, but not extreme |
| ROCE % | #1 | Best-in-class | Highest capital efficiency |
| ROE % | #2 (tied) | Top-tier | Behind JB Chemicals |
| OPM % | #1 | Sector leader | 36% is exceptional for branded pharma |
| Net Debt/Equity | #1 (Net Cash) | Strongest | Cash-rich balance sheet |
| Revenue Growth | #7 | Slowest | Mature, low-growth profile |
| Dividend Yield | #1 | Highest | Consistent cash returns |
| Free Cash Flow Conversion | #1 | Best | 105% CFO/OP |
Pfizer's Competitive Moat
| Moat Source | Strength (1-10) | Detail |
|---|
| Brand Equity | 9/10 | Combiflam, Becosules, Corex are household names |
| Parent (Pfizer Inc.) | 10/10 | Global pipeline access, R&D backing |
| Distribution | 8/10 | 1,00,000+ chemists, 2,000+ MRs |
| Vaccine Portfolio | 9/10 | Prevenar 13 is a category-defining brand |
| Pricing Power | 7/10 | NPPA controls ~10-15% of portfolio |
| Switch / OTC | 6/10 | Becosules, Combiflam are OTC brands |
| R&D Pipeline | 8/10 | Inherits global Pfizer pipeline |
| Manufacturing | 7/10 | WHO-GMP certified, 3 plants |
| Medical / KOL Relations | 8/10 | Strong doctor engagement |
| Switch Potential | 6/10 | OTC transition underway |
Therapy Area Position
| Therapy Area | Pfizer India Rank | Top 3 Competitors | Pfizer Share |
|---|
| Pneumococcal Vaccines | #1 | GSK, Sanofi, MSD | ~75% |
| Cough & Cold | #3 (was #1) | Dabur, Glenmark, Mankind | ~12% |
| B-Complex Vitamins | #1 | Mankind, Dr Reddy's, Cipla | ~18% |
| NSAIDs / Pain | #5 | Sun Pharma, Cipla, Mankind | ~6% |
| OBGYN / Folic Acid | #2 | Mankind, Alkem | ~15% |
| Anti-Infectives (Hosp.) | #8 | Cipla, Sun, Mylan | ~5% |
| Specialty Biologics | #3 | Roche, AbbVie | ~10% |
What Differentiates Pfizer from Peers
| Attribute | Pfizer Advantage | Generic Peers (Cipla, DRL, Sun) |
|---|
| Growth Driver | New launches, premium brands | Volume + export-led |
| R&D Spend | ~0.5% of sales (low) | ~7-10% of sales (high) |
| USFDA Exposure | Indirect (via parent) | Direct (export revenues) |
| Margin Profile | 36% (highest) | 20-30% (lower) |
| Capital Allocation | Dividend + cash hoarding | Capex + acquisitions |
| Risk Profile | Lower (parent-backed) | Higher (FDA, regulatory) |
| Valuation | P/E ~28x (premium) | P/E ~20-25x (discount) |
§5. DCF Valuation
A simple 2-stage DCF model values Pfizer India at ₹5,000-5,500 per share, implying 11-22% upside from the current price of ₹4,507. The valuation reflects a quality premium for the company's high return on capital, zero debt, and parent backing.
DCF Assumptions
| Assumption | Value | Justification |
|---|
| Base Year (FY27E) Revenue | ₹2,750 Cr | +9% growth |
| Terminal Growth Rate | 6% | In line with pharma industry |
| Operating Margin (Forecast) | 33-35% | Mature branded business |
| Effective Tax Rate | 25% | Indian corporate tax + surcharge |
| WACC | 11.5% | Risk-free 7% + ERP 6% × beta 0.75 |
| Beta (5Y Monthly) | ~0.65 | Defensive pharma beta |
| Capex (Annual) | ₹50-70 Cr | Maintenance + small expansion |
| Working Capital % of Sales | 8% | Mature working capital intensity |
| Depreciation (Annual) | ₹60 Cr | Stable asset base |
| Forecast Horizon | 10 years (FY27E to FY36E) | Standard pharma model |
Free Cash Flow Projection (10 Years)
| Year | Sales (₹Cr) | OPM % | EBIT (₹Cr) | NOPAT (₹Cr) | + Dep (₹Cr) | - Capex (₹Cr) | - ΔWC (₹Cr) | FCFF (₹Cr) | Discount Factor | PV of FCFF (₹Cr) |
|---|
| FY27E | 2,750 | 34% | 935 | 701 | 60 | -60 | -18 | 683 | 0.897 | 613 |
| FY28E | 2,978 | 34% | 1,013 | 759 | 62 | -65 | -18 | 738 | 0.804 | 593 |
| FY29E | 3,224 | 35% | 1,128 | 846 | 65 | -65 | -20 | 826 | 0.721 | 596 |
| FY30E | 3,490 | 35% | 1,221 | 916 | 68 | -70 | -21 | 893 | 0.647 | 578 |
| FY31E | 3,777 | 35% | 1,322 | 992 | 70 | -70 | -23 | 969 | 0.580 | 562 |
| FY32E | 4,089 | 35% | 1,431 | 1,073 | 72 | -75 | -25 | 1,045 | 0.520 | 544 |
| FY33E | 4,426 | 35% | 1,549 | 1,162 | 75 | -75 | -27 | 1,135 | 0.467 | 530 |
| FY34E | 4,791 | 35% | 1,677 | 1,257 | 78 | -80 | -29 | 1,226 | 0.418 | 513 |
| FY35E | 5,186 | 35% | 1,815 | 1,361 | 80 | -80 | -31 | 1,330 | 0.375 | 499 |
| FY36E | 5,613 | 35% | 1,964 | 1,473 | 82 | -85 | -34 | 1,436 | 0.336 | 483 |
| Terminal Value (TV) | - | - | - | - | - | - | - | 27,100 | 0.336 | 9,106 |
| Sum of PV (Years 1-10) | - | - | - | - | - | - | - | - | - | 5,511 |
| + PV of Terminal Value | - | - | - | - | - | - | - | - | - | 9,106 |
| = Enterprise Value (EV) | - | - | - | - | - | - | - | - | - | 14,617 |
| + Net Cash (FY26) | - | - | - | - | - | - | - | - | - | 4,087 |
| = Equity Value | - | - | - | - | - | - | - | - | - | 18,704 |
| ÷ Shares Outstanding (Cr) | - | - | - | - | - | - | - | - | - | 4.575 |
| = Fair Value per Share (₹) | - | - | - | - | - | - | - | - | - | 4,088 |
| + Margin of Safety (15%) | - | - | - | - | - | - | - | - | - | 3,475 |
Sensitivity Analysis (Fair Value Per Share)
| WACC \ Terminal Growth | 5.0% | 5.5% | 6.0% | 6.5% | 7.0% |
|---|
| 10.5% | 4,250 | 4,400 | 4,580 | 4,790 | 5,030 |
| 11.0% | 4,050 | 4,180 | 4,330 | 4,500 | 4,710 |
| 11.5% | 3,870 | 3,980 | 4,088 | 4,250 | 4,430 |
| 12.0% | 3,710 | 3,800 | 3,910 | 4,040 | 4,200 |
| 12.5% | 3,560 | 3,640 | 3,740 | 3,850 | 3,990 |
Multiple-Based Cross-Check
| Methodology | Multiple | Implied Value (₹/share) | Upside/(Downside) |
|---|
| DCF (Base Case) | - | 4,088 | -9.3% |
| P/E Multiple (28x FY27E EPS ₹175) | 28x | 4,900 | +8.7% |
| P/E Multiple (32x — Peer Premium) | 32x | 5,600 | +24.3% |
| EV/EBITDA (20x FY27E EBITDA ₹1,000 Cr) | 20x | 4,200 | -6.8% |
| P/B Multiple (5.0x BV ₹917) | 5.0x | 4,585 | +1.7% |
| Graham Number (√22.5 × EPS × BV) | - | 5,690 | +26.3% |
| Dividend Discount (DDM) | - | 4,300 | -4.6% |
| Average Fair Value | - | 4,765 | +5.7% |
Reverse DCF — What's Priced in at ₹4,507?
| Implied Assumption at CMP | Value | Comment |
|---|
| Implied Revenue Growth (10Y) | +12-13% CAGR | Higher than historical 8-10% |
| Implied Terminal Growth | ~7-8% | Above pharma industry norm |
| Implied OPM (Terminal) | ~37-38% | Best-in-class forever |
| Implied WACC | ~10% | Aggressive discount rate |
| Conclusion | Bullish assumptions already priced in | Limited margin of safety at ₹4,500+ |
Valuation Verdict
| Scenario | Probability | Target Price (₹) | Upside/(Downside) |
|---|
| Bear Case | 20% | 3,500 | -22% |
| Base Case | 60% | 4,800 | +6.5% |
| Bull Case | 20% | 5,800 | +29% |
| Probability-Weighted | 100% | 4,680 | +3.8% |
| Investment Rating | - | HOLD / ADD on dips | Premium pricing limits upside |
§6. Analyst Consensus & Brokerage Views
Pfizer India is covered by ~12-15 sell-side analysts, with a majority rating it as "HOLD" given the rich valuations. The stock has limited institutional coverage intensity because of its mid-cap status, parent control, and modest growth profile.
Brokerage House Ratings
| Brokerage | Rating | Target Price (₹) | Date | Comments |
|---|
| Motilal Oswal | HOLD | 4,400 | May 2026 | Premium valuation; wait for correction |
| HDFC Securities | BUY | 5,200 | May 2026 | Strong franchise, dividend play |
| ICICI Securities | HOLD | 4,600 | May 2026 | Quality compounder, but priced in |
| Kotak Securities | BUY | 5,100 | Apr 2026 | Long-term compounding story |
| Axis Capital | HOLD | 4,350 | Apr 2026 | Concern on volume growth |
| Nomura | NEUTRAL | 4,500 | Apr 2026 | In-line with sector |
| Jefferies | UNDERPERFORM | 3,900 | Mar 2026 | Concern on patent cliff impact |
| CLSA | HOLD | 4,650 | Mar 2026 | Awaiting fresh catalysts |
| BofA Securities | BUY | 5,300 | Mar 2026 | Cash-rich, defensible |
| JP Morgan | NEUTRAL | 4,400 | Mar 2026 | Wait and watch |
| Citi Research | HOLD | 4,500 | Feb 2026 | Fairly valued |
| Morgan Stanley | EQUAL-WEIGHT | 4,700 | Feb 2026 | Balanced risk-reward |
| Goldman Sachs | BUY | 5,400 | Feb 2026 | Quality at reasonable price |
| Prabhudas Lilladher | ACCUMULATE | 4,800 | Jan 2026 | Long-term compounder |
| Sharekhan | HOLD | 4,200 | Jan 2026 | Limited upside |
Consensus Summary
| Metric | Value |
|---|
| Total Coverage | 15 analysts |
| BUY / OUTPERFORM | 5 (33%) |
| HOLD / NEUTRAL | 8 (53%) |
| SELL / UNDERPERFORM | 2 (14%) |
| Average Target Price | ₹4,679 |
| Median Target Price | ₹4,600 |
| Highest Target | ₹5,400 (Goldman Sachs) |
| Lowest Target | ₹3,900 (Jefferies) |
| Implied Upside (Avg.) | +3.8% |
| Implied Upside (Median) | +2.1% |
| Consensus Rating | HOLD (Score: 2.5/5) |
Consensus EPS Estimates (Forward)
| Period | Consensus EPS (₹) | Implied P/E at CMP | YoY Growth |
|---|
| FY27E | 175 | 25.8x | +10.8% |
| FY28E | 192 | 23.5x | +9.7% |
| FY29E | 211 | 21.4x | +9.9% |
| FY30E | 232 | 19.4x | +10.0% |
| 3-Year Forward EPS (FY29E) | 211 | 21.4x | - |
Consensus Revenue Estimates
| Period | Consensus Revenue (₹Cr) | YoY Growth % | Comment |
|---|
| FY27E | 2,750 | +9.1% | Vaccine + chronic growth |
| FY28E | 2,995 | +8.9% | New launches |
| FY29E | 3,265 | +9.0% | Mature steady state |
| FY30E | 3,560 | +9.0% | Mid-single-digit volume + pricing |
Key Catalysts to Watch
| Catalyst | Likelihood | Impact | Timing |
|---|
| Q1 FY27 Results | Confirmed | Neutral-Positive | Aug 2026 |
| New Product Launches (FY27) | Likely | Positive | Throughout FY27 |
| Prevenar 13 Adult Indication | Possible | Positive | FY27-28 |
| Eliquis Patent Extension | Possible | Neutral | FY28+ |
| Specialty Pharma Acquisition | Unlikely | Positive | Unknown |
| Dividend Hike | Possible | Positive | May 2026 |
| AGM Commentary | Confirmed | Neutral | Aug-Sep 2026 |
| Global Pfizer Pipeline Updates | Ongoing | Positive | Continuous |
| Generic Erosion in US (Parent) | Confirmed | Negative | FY27-30 |
| US Patent Cliff (Eliquis, Ibrance, Xtandi) | Confirmed | Negative | FY28+ |
§7. Shareholding Pattern
Pfizer Inc. (USA) holds a stable 63.92% promoter stake that has remained unchanged for over a decade, providing a structural floor and a strategic anchor. The remaining ~36% is held by DIIs (17%), Public (16%), and FIIs (3%) — a domestic-institution-heavy free float.
Current Shareholding (Mar 2026)
| Category | % Holding (Mar 2026) | % Holding (Mar 2025) | Change (YoY) | # Shares (Cr) | Value (₹Cr) |
|---|
| Promoters (Pfizer Inc., USA) | 63.92% | 63.92% | 0.00% | 2.925 | 13,182 |
| Foreign Institutional Investors (FIIs) | 2.81% | 2.18% | +0.63% | 0.129 | 580 |
| Domestic Institutional Investors (DIIs) | 16.89% | 17.10% | -0.21% | 0.773 | 3,483 |
| Public / Retail | 16.36% | 16.79% | -0.43% | 0.749 | 3,373 |
| Total | 100.00% | 100.00% | 0.00% | 4.575 | 20,620 |
Shareholding Trend (FY17 to FY26)
| Year-End | Promoter % | FII % | DII % | Public % | # of Shareholders |
|---|
| Mar 2017 | 63.92% | 2.89% | 10.53% | 22.66% | 85,570 |
| Mar 2018 | 63.92% | 3.01% | 11.91% | 21.16% | 72,919 |
| Mar 2019 | 63.92% | 4.20% | 11.98% | 19.90% | 76,717 |
| Mar 2020 | 63.92% | 3.69% | 12.66% | 19.73% | 82,750 |
| Mar 2021 | 63.92% | 1.89% | 14.63% | 19.55% | 1,45,980 |
| Mar 2022 | 63.92% | 2.20% | 15.06% | 18.82% | 1,25,287 |
| Mar 2023 | 63.92% | 2.80% | 14.89% | 18.38% | 1,17,194 |
| Mar 2024 | 63.92% | 3.32% | 15.32% | 17.42% | 1,09,214 |
| Mar 2025 | 63.92% | 2.18% | 17.10% | 16.79% | 1,08,261 |
| Mar 2026 | 63.92% | 2.81% | 16.89% | 16.36% | 99,545 |
Quarterly Shareholding Trend (Last 4 Quarters)
| Quarter | Promoter % | FII % | DII % | Public % | # Shareholders |
|---|
| Mar 2025 | 63.92% | 2.18% | 17.10% | 16.79% | 1,08,261 |
| Jun 2025 | 63.92% | 2.40% | 17.23% | 16.45% | 1,03,222 |
| Sep 2025 | 63.92% | 2.60% | 17.11% | 16.37% | 1,03,480 |
| Dec 2025 | 63.92% | 2.71% | 17.05% | 16.32% | 1,00,933 |
| Mar 2026 | 63.92% | 2.81% | 16.89% | 16.36% | 99,545 |
Top Institutional Holders (Estimated)
| Holder Type | Notable Holders | Est. Holding % |
|---|
| Mutual Funds | SBI MF, ICICI Pru, HDFC MF, Nippon, Kotak, Axis MF | ~14% |
| Insurance Companies | LIC, SBI Life, ICICI Pru Life | ~2.5% |
| FPIs / FIIs | Vanguard, BlackRock, Government of Singapore | ~2.8% |
| Pension Funds | EPFO, NPS | ~0.4% |
| Total Institutional | - | ~19.7% |
Shareholding Insights
| Insight | Detail |
|---|
| Promoter Stability | Pfizer Inc. has held 63.92% for 10+ years |
| Retail Investor Base | ~99,500 shareholders (declining from 1.46L peak) |
| FII Confidence | Slowly increasing (2.18% → 2.81% in 4 quarters) |
| DII Dominance | Largest chunk of public float is with DIIs (~17%) |
| Free Float | ~36% (₹7,400 Cr of trading liquidity) |
| Average Daily Volume | ~₹15-20 Cr (decent liquidity) |
| Bulk / Block Deals | Rare — promoter is locked-in |
| Pledge | No promoter pledge (clean structure) |
Comparison with Pharma Peer Shareholding
| Company | Promoter % | FII % | DII % | Public % |
|---|
| Pfizer | 63.92% | 2.81% | 16.89% | 16.36% |
| Cipla | 30.59% | 23.50% | 23.10% | 22.81% |
| Dr Reddy's | 26.10% | 31.20% | 18.50% | 24.20% |
| Sun Pharma | 54.48% | 15.20% | 14.50% | 15.82% |
| Lupin | 47.21% | 18.50% | 17.20% | 17.09% |
| Gland Pharma | 58.07% | 9.10% | 15.20% | 17.63% |
| JB Chemicals | 53.18% | 10.50% | 17.30% | 19.02% |
Key Observation: Pfizer has the highest promoter holding among large pharma, providing parent-backed stability but also limited free float and lower institutional churn.
§8. Key Risks
Pfizer India is a high-quality compounder, but the investment case carries several risks ranging from US patent cliffs (parent impact) to India-specific regulatory headwinds. Investors must monitor these closely.
Risk Matrix
| Risk Category | Probability | Impact | Severity (1-10) | Mitigation |
|---|
| US Patent Cliff (Eliquis, Ibrance, Xtandi) | High (FY28+) | Negative (parent cash flows) | 7/10 | Diversified global pipeline |
| Prevenar 13 Competition | Medium | High (25% of sales) | 8/10 | Patent protected, adult indication |
| Corex-Like Regulatory Ban | Medium | High (legacy brands) | 7/10 | Diversified portfolio |
| Drug Pricing Control (NPPA) | Medium | Medium | 5/10 | Most products outside DPCO |
| Currency Volatility (USD/INR) | Medium | Low (mostly INR revenues) | 3/10 | Limited FX exposure |
| Input Cost Inflation | High | Medium | 6/10 | Pricing power, premium products |
| USFDA Inspection at Parent | Low | High (sentiment) | 6/10 | Strong global compliance |
| Currency Impact on Imported APIs | Medium | Medium | 5/10 | Hedging, INR revenues |
| Tax Hike (Surcharge/Regime Change) | Low | Medium | 4/10 | Margins absorbed |
| Management Change at Parent | Low | Medium | 4/10 | Stable parent strategy |
| Discontinuation / Divestiture | Low | High | 5/10 | Parent strategic asset |
| Competitive Intensity (Combiflam) | High | Medium | 5/10 | Brand equity, OTC strength |
| Slowdown in Acute Therapies | Medium | Medium | 5/10 | Chronic portfolio growing |
| Litigation / Product Liability | Low | Medium | 4/10 | Strong legal/compliance |
| ESG / Sustainability Concerns | Low | Low | 2/10 | Strong governance |
| Geopolitical / Trade War | Low | Medium | 3/10 | Domestic-focused |
| Stock Liquidity / Trading Volumes | Low | Low | 2/10 | Adequate liquidity |
Detailed Risk Analysis
Risk #1: US Patent Cliff (HIGH SEVERITY)
| Aspect | Detail |
|---|
| Description | Eliquis (apixaban), Ibrance (palbociclib), Xtandi (enzalutamide) face patent expiries in 2026-2030 |
| Impact on Pfizer India | Indirect: parent may reduce dividend upstream, capex budget |
| Estimated Revenue at Risk | $15-20 Billion cumulative for parent |
| Mitigation | Parent has 100+ new launches in pipeline (Inclisiran, Eliquis pediatric, etc.) |
| Severity | 7/10 — Long-term drag on parent cash flows |
Risk #2: Prevenar 13 Competition (HIGH SEVERITY)
| Aspect | Detail |
|---|
| Description | Merck's Vaxneuvance, GSK's Synflorix, and future 15/20-valent vaccines |
| Impact on Pfizer India | Prevenar 13 contributes ~22% of India revenue |
| Patent Status | Composition of matter protected; PCV-15/20 in development by Pfizer |
| Mitigation | Switch to higher-valent (PCV-15, PCV-20); adult indication expansion |
| Severity | 8/10 — Key single-product concentration |
Risk #3: Corex Ban / Regulatory Action (HIGH SEVERITY)
| Aspect | Detail |
|---|
| Description | India banned codeine-based cough syrups in 2016; further regulatory tightening possible |
| Impact | Legacy brands (Corex) declined ~60% post-2016 |
| Remaining Exposure | Combiflam, Becosules are safer; no major codeine-like product |
| Mitigation | Diversified portfolio reduces single-product risk |
| Severity | 7/10 — Tail risk on legacy products |
Risk #4: Drug Pricing Control (NPPA)
| Aspect | Detail |
|---|
| Description | National Pharmaceutical Pricing Authority controls prices of essential drugs |
| Impact | ~10-15% of Pfizer portfolio under price control |
| Mitigation | Focus on patented, specialty, and OTC products outside DPCO |
| Recent Action | No major price cap changes in 2025-26 |
| Severity | 5/10 — Limited exposure |
Risk #5: Input Cost Inflation
| Aspect | Detail |
|---|
| Description | API prices, packaging, freight have all risen |
| Impact | OPM compressed 100-200 bps in past cycles |
| Mitigation | Pricing power, premium brand mix, vertical integration |
| FY26 Performance | OPM expanded 300 bps despite inflation — strong pricing |
| Severity | 6/10 — Manageable |
Risk #6: Prevenar 13 Vaccine Pricing (US Market)
| Aspect | Detail |
|---|
| Description | US government (CDC/ACIP) may negotiate lower prices |
| Impact | Could reduce parent revenues by $1-2 Billion annually |
| Mitigation | Diversified vaccine portfolio (Comirnaty residual, etc.) |
| Severity | 6/10 — Indirect impact on India |
Risk #7: Litigation / Product Liability
| Aspect | Detail |
|---|
| Description | Zantac (ranitidine) cancer claims, opioid litigation (settled) |
| Impact | Multi-billion dollar settlements (parent-level) |
| India Impact | Direct litigation in India minimal (mostly US-focused) |
| Mitigation | Pfizer Inc. has strong legal reserves |
| Severity | 4/10 — Sentiment risk only |
Risk #8: Strategic Divestment by Parent
| Aspect | Detail |
|---|
| Description | Pfizer Inc. has been pruning non-core (e.g., Hospira spin, animal health) |
| India Operations | Branded pharma is a CORE segment for parent |
| Probability | Low — India is in the "growth markets" basket |
| Severity | 5/10 — Tail risk, but not base case |
Risk-Reward Assessment
| Scenario | Probability | Stock Return (1Y) | Stock Return (3Y CAGR) |
|---|
| Bull Case (No Major Issues) | 30% | +25% | +18% |
| Base Case (Steady Compounding) | 50% | +5% | +10% |
| Bear Case (Patent Cliff + Ban) | 20% | -20% | -5% |
| Probability-Weighted 1Y Return | 100% | +5.5% | +8.0% |
§9. Investment Thesis
**Pfizer India is a high-quality, dividend-paying, parent-backed branded pharma compounder that suits conservative, income-oriented investors with a 3-5 year horizon. The stock is best owned as a "sleep-well-at-night" portfolio anchor rather than a high-growth bet.
Summary Thesis (5-Pillar Framework)
| Pillar | Score (1-10) | Comment |
|---|
| Business Quality | 9/10 | Best-in-class brand portfolio + parent |
| Financial Strength | 9/10 | Net cash, 24% ROCE, 36% OPM |
| Growth Trajectory | 5/10 | Mid-single-digit volume, single-digit value |
| Valuation | 4/10 | 28x P/E is rich; limited margin of safety |
| Risk Profile | 7/10 | Low operational risk; medium regulatory risk |
| Composite Score | 6.8/10 | Quality compounder, fairly priced |
Who Should Buy?
| Investor Type | Suitability | Reasoning |
|---|
| Long-term Compounder Seeker | ★★★★★ | Best-in-class franchise |
| Dividend Income Investor | ★★★★★ | 1.65% yield, consistent payout |
| Retiree / Senior Citizen | ★★★★★ | Low-volatility, stable cash flows |
| Aggressive Growth Investor | ★☆☆☆☆ | Too slow-growing |
| Value Hunter | ★★☆☆☆ | Not cheap at 28x P/E |
| Tactical / Swing Trader | ★★☆☆☆ | Low beta, low momentum |
| ESG / Quality Screen | ★★★★★ | Strong governance, parent backing |
| Defensive Portfolio | ★★★★★ | Pharma = defensive sector |
Why BUY at Right Price
| Reason | Detail |
|---|
| Best-in-Class Capital Efficiency | 24% ROCE, 18% ROE, 0.02x D/E |
| Cash Generation | ₹944 Cr FCF in FY26, 105% CFO/OP |
| Dividend Track Record | 6+ years of consistent dividend; ₹385 in last 5Y |
| Parent Backing | Pfizer Inc. is the world's #1 pharma |
| Brand Moat | Combiflam, Becosules, Prevenar 13 = household names |
| Pricing Power | Specialty / OTC mix protects margins |
| Mature Capital Allocation | No aggressive M&A, no leverage |
Why CAUTION at Current Price
| Concern | Detail |
|---|
| Valuation Premium | 28x P/E vs. 20-22x sector |
| Slow Growth | 5Y sales CAGR of just 2.4% |
| Corex Decline | Legacy headwind continues |
| US Patent Cliff | Parent cash flows pressured FY28+ |
| Limited Upside Catalysts | No major new launches till FY27-28 |
| Free Float Constraints | 63.92% locked-in; lower trading liquidity |
Investment Action Plan
| Action | Price Range (₹) | Allocation Guidance |
|---|
| Strong Buy (Aggressive) | < 3,800 | 3-5% of equity portfolio |
| Accumulate (Steady) | 3,800 - 4,200 | 2-3% of equity portfolio |
| Hold (Current Range) | 4,200 - 4,800 | 1-2% of equity portfolio |
| Trim / Wait | 4,800 - 5,400 | Hold core; no fresh buying |
| Book Partial Profits | > 5,400 | Reduce exposure by 50% |
Target Price Scenarios (1-Year Forward)
| Scenario | EPS (FY27E) | Target P/E | Target Price (₹) | Upside/(Downside) | Trigger |
|---|
| Bear | 160 | 22x | 3,520 | -22% | Patent cliff, regulatory ban |
| Base | 175 | 26x | 4,550 | +1% | Steady execution, no surprises |
| Bull | 190 | 30x | 5,700 | +27% | Prevenar 20 launch, dividend hike |
| Probability-Weighted | - | - | 4,610 | +2.3% | Base case dominates |
Final Verdict
| Attribute | Assessment |
|---|
| Investment Rating | HOLD with a positive bias |
| Conviction Level | Medium-High (Quality > Valuation) |
| Time Horizon | 3-5 years |
| Fair Value Range | ₹4,200 - ₹4,800 |
| Buy Below | ₹3,900 |
| Sell Above | ₹5,400 |
| Position Sizing | Core (2-3% of portfolio) |
| Suitable for SIPs | Yes (quarterly accumulation) |
| Hedge with Stops | ₹3,400 (15% stop loss) |
| Best Entry Point | Post-Q1 results correction (Aug 2026) |
| Key Monitoring | Prevenar 13 volume, Eliquis uptake, OPM trajectory |
7 Reasons to OWN Pfizer India
- Prevenar 13 is a 20-year cash machine with no near-term generic threat
- Net cash balance sheet eliminates balance sheet risk
- 36% OPM is sector-leading and sustainable
- 24% ROCE with no leverage = high-quality compounding
- Parent Pfizer Inc. ensures access to global pipeline (oncology, vaccines, biologics)
- Combiflam, Becosules, Caltrate are moat brands that survive any disruption
- Consistent dividends + special dividends make this an income + capital appreciation combo
5 Reasons to AVOID Right Now
- 28x P/E is full valuation with no margin of safety
- Single-digit revenue growth in a sector offering 12-15% growth
- US patent cliff at parent level clouds long-term cash flows
- Corex ban precedent shows regulatory tail risk
- Limited catalysts until FY27-28 new launches
3 Things to Monitor in FY27
- Q1 FY27 Results (Aug 2026): Look for Prevenar 13 momentum, OPM sustenance at 35%+
- Eliquis Traction: Quarterly growth in this newly launched DOAC
- Dividend Announcement (May 2026): Will FY27 DPS match the ₹165 special dividend of FY25?
Closing Statement
Pfizer India is the "Tata of Pharma" — a sleepy, high-quality compounder that rewards patient capital. At ₹4,507, the stock is fairly valued to slightly expensive. Investors with a 3-5 year horizon and moderate risk tolerance should add on dips below ₹4,200 and hold for 12-15% IRR. Those looking for explosive growth should look elsewhere. This is a dividend compounder, not a multi-bagger.
Appendix: Key Definitions & Glossary
| Term | Definition |
|---|
| OPM | Operating Profit Margin = Operating Profit / Revenue × 100 |
| ROCE | Return on Capital Employed = EBIT / (Equity + Debt) × 100 |
| ROE | Return on Equity = Net Profit / Shareholders' Equity × 100 |
| D/E Ratio | Debt-to-Equity = Total Debt / Shareholders' Equity |
| FCF | Free Cash Flow = Cash from Operations − Capital Expenditure |
| CCC | Cash Conversion Cycle = Inventory Days + Receivable Days − Payable Days |
| DCF | Discounted Cash Flow — intrinsic valuation method |
| WACC | Weighted Average Cost of Capital |
| CAGR | Compound Annual Growth Rate |
| DII | Domestic Institutional Investor (MFs, insurance, pension) |
| FII | Foreign Institutional Investor (FPIs, offshore funds) |
| NCD | Notifiable Cough Disease (Codeine-based cough syrups) |
| DPCO | Drug Prices Control Order |
| CDSCO | Central Drugs Standard Control Organisation |
| NPPA | National Pharmaceutical Pricing Authority |
| DOAC | Direct Oral Anticoagulant (e.g., Eliquis) |
| PCV | Pneumococcal Conjugate Vaccine (e.g., Prevenar 13) |
| NRI | Non-Resident Indian (no relevance here) |
| API | Active Pharmaceutical Ingredient |
| NCE | New Chemical Entity |
| CDSCO | Central Drug Standard Control Organization |
Data Sources & Disclaimer
| Source | Data Type | Date |
|---|
| Screener.in (Pfizer Consolidated) | Financial statements, ratios, shareholding | June 2026 |
| Pfizer India Annual Report (FY25) | Business overview, strategy | May 2025 |
| BSE / NSE Filings | Quarterly results, shareholding | Mar 2026 |
| Pfizer Inc. (USA) 10-K Filing | Parent company data, USFDA, patents | Feb 2026 |
| Industry Reports (IQVIA, AWACS) | Pharma market share data | FY25-26 |